Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 Next >
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the 2025 Psychedelic Science Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate at the 28th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides Corporate Update on Upcoming Clinical Milestones
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.